-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
German pharmaceutical giant Merck (Merck KGaA) recently announced data from a placebo-controlled randomized phase II trial at the 73rd American Academy of Neurology (AAN) annual meeting in 2021.
It is worth mentioning that evobrutinib is the first and only BTK inhibitor that has been proven to reduce key biomarkers of nerve damage and inflammation in MS patients.
Professor Jens Kuhle, Director of the Multiple Sclerosis Center of the University Hospital of Basel, Switzerland, said: “NfL in blood is a biomarker that can monitor disease activity and treatment response.
In this placebo-controlled phase II trial of evobrutinib in patients with relapsing multiple sclerosis (RMS), a post-hoc analysis evaluated 166 patients with baseline NfL values and at least one post-baseline NfL value.
The main results from this phase II study were published in the New England Journal of Medicine in 2019.
In another oral report at the AAN annual meeting, BTK and activated (phosphorylated) BTK (pBTK) levels in B cells isolated from RMS patients were tested.
In addition, an exploratory analysis to be announced at the triMS online conference on May 27 evaluated the relationship between the distribution of evobrutinib in the cerebrospinal fluid (CSF) of RMS patients and the plasma concentration.
Danny Bar Zohar, MD, Global Head of Business Development at Merck Healthcare, said: “In summary, the current preclinical and clinical data show that evobrutinib can inhibit MS mechanisms involved in disease activity and progression.
The chemical structure of evobrutinib (picture source: medchemexpress.
Multiple sclerosis (MS) is a chronic inflammatory central nervous system disease and the most common non-traumatic, disabling neurological disease in young people.
Evobrutinib (M2951) is currently in clinical development to explore its potential as a treatment for multiple sclerosis (MS).
Evobrutinib is designed to inhibit major B cell responses, such as proliferation, the release of antibodies and cytokines, without directly affecting T cells.
Original source: Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
Original Title: New Drug for Multiple Sclerosis (MS)! Merck evobrutinib: the first BTK inhibitor to reduce key biomarkers of nerve damage/inflammation!
